Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy.

Lazarevic B, Hammarström C, Yang J, Ramberg H, Diep LM, Karlsen SJ, Kucuk O, Saatcioglu F, Taskèn KA, Svindland A.

Br J Nutr. 2012 Dec 28;108(12):2138-47. doi: 10.1017/S0007114512000384. Epub 2012 Mar 8.

PMID:
22397815
2.

Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells.

Shen JC, Klein RD, Wei Q, Guan Y, Contois JH, Wang TT, Chang S, Hursting SD.

Mol Carcinog. 2000 Oct;29(2):92-102.

PMID:
11074606
3.

Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.

Bass R, Perry B, Langenstroer P, Thrasher JB, Dennis KL, Tawfik O, Holzbeierlein J.

J Urol. 2009 Feb;181(2):615-9; discussion 619-20. doi: 10.1016/j.juro.2008.10.029. Epub 2008 Dec 16.

PMID:
19091346
5.
6.

Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial.

Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H, Moen A, Wessel N, Berg RE, Egge-Jacobsen W, Hammarstrom C, Svindland A, Kucuk O, Saatcioglu F, Taskèn KA, Karlsen SJ.

Nutr Cancer. 2011;63(6):889-98. doi: 10.1080/01635581.2011.582221. Epub 2011 Jun 29.

PMID:
21714686
7.

Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer.

Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schröder FH, van der Kwast TH.

J Urol. 2000 Dec;164(6):2156-61.

PMID:
11061947
8.

Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.

Avgeris M, Stravodimos K, Scorilas A.

Prostate. 2011 Dec;71(16):1780-9. doi: 10.1002/pros.21395. Epub 2011 Apr 25.

PMID:
21520157
9.

Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.

Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G.

Urology. 2007 Dec;70(6):1225-9.

PMID:
18158066
10.

Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy.

Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, Khachik F, Li YW, Banerjee M, Grignon D, Bertram JS, Crissman JD, Pontes EJ, Wood DP Jr.

Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):861-8.

11.

Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer.

Vis AN, van Rhijn BW, Noordzij MA, Schröder FH, van der Kwast TH.

J Pathol. 2002 Jun;197(2):148-54.

PMID:
12015737
12.
13.

Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands.

Monsef N, Helczynski L, Lundwall A, Påhlman S; Anders-Bjartell.

Prostate. 2007 Aug 1;67(11):1219-29.

PMID:
17562539
14.

Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients.

Swami S, Krishnan AV, Moreno J, Bhattacharyya RS, Gardner C, Brooks JD, Peehl DM, Feldman D.

Int J Cancer. 2009 May 1;124(9):2050-9. doi: 10.1002/ijc.24161.

15.

Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies.

Ricciardelli C, Bianco-Miotto T, Jindal S, Dodd TJ, Cohen PA, Marshall VR, Sutherland PD, Samaratunga H, Kench JG, Dong Y, Wang H, Clements JA, Risbridger GP, Sutherland RL, Tilley WD, Horsfall DJ; Australian Prostate Cancer BioResource.

Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1755-65. doi: 10.1158/1055-9965.EPI-10-0059.

16.

A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus.

Kaushal A, Myers SA, Dong Y, Lai J, Tan OL, Bui LT, Hunt ML, Digby MR, Samaratunga H, Gardiner RA, Clements JA, Hooper JD.

Prostate. 2008 Mar 1;68(4):381-99. doi: 10.1002/pros.20685.

PMID:
18196551
17.
18.

Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.

deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, Sun B.

Urology. 2004 Feb;63(2):259-63.

PMID:
14972467
19.

Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.

Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L.

J Urol. 2002 Sep;168(3):1204-11.

PMID:
12187268
20.

Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy.

Amamoto R, Yagi M, Song Y, Oda Y, Tsuneyoshi M, Naito S, Yokomizo A, Kuroiwa K, Tokunaga S, Kato S, Hiura H, Samori T, Kang D, Uchiumi T.

Cancer Sci. 2011 Mar;102(3):639-47. doi: 10.1111/j.1349-7006.2010.01828.x. Epub 2011 Jan 23.

Supplemental Content

Support Center